Editorial Perspectives On Cell Line Development

  1. A Differentiated Approach To Allogeneic Cell Therapy Manufacturing 3/3/2021

    Celyad Oncology CEO Filippo Petti digs in on differentiating his company’s approach to developing and manufacturing allogeneic cell therapies for several oncology indications, including the company's technology platform and scale-up strategies in Celyad’s Belgium-based clinical manufacturing facility.  

  2. Genetically Engineering An IL-15 Superagonist 9/25/2020

    SOTIO’s genetically-engineered SO-C101 is showing promise as a monotherapy and combined with immunotherapies in pre-clinical tests and also recently in a phase I study. CBO Jens Hennecke, Ph.D. shared an update on the company’s Phase 1 progress and gave us a look behind the curtains at the work it took to get to the clinic.